On Friday, the FDA approved Evofem Biosciences Inc.'s Phexxi contraceptive gel. The stock is up sharply Tuesday morning so let's check out a few charts to give us some reference points. In the daily bar chart of EVFM, below, we can see a sideways to lower trend the past 12 months.
In the current session, Evofem Biosciences Inc. (NASDAQ: EVFM) is trading at $6.04, after a 21% increase. Over the past month, the stock increased by 25.57%, and in the past year, by 2.03%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently down from its 52 week high by 19.47%.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of 0.0 in the biotechnology industry, Evofem Biosciences has a higher P/E ratio of 0.0. Shareholders might be inclined to think that Evofem Biosciences might perform better than its industry group. It's also possible that the stock is overvalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * Stocks That Hit 52-Week Highs On Tuesday * P/E Ratio Insights for Fly Leasing * 9 Consumer Defensive Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The company said earlier in May it was looking to price the contraceptive gel, Phexxi, between $250 and $275 for a box of 12 packs. The gel is a rare new addition to the $5.5 billion U.S. contraceptive market, which is dominated by male condoms and hormonal birth control pills for women, known to cause a host of side effects such as bleeding between periods, mood swings and nausea. The only non-hormonal contraceptive in the market has been the copper-based intrauterine devices, such as Cooper Surgical's ParaGard, which are often associated with bleeding and cramps, causing many to remove the implants within the first year.
Q1 2020 Evofem Biosciences Inc Earnings Call
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today reported financial results for the three-month period ended March 31, 2020.
Companies In The News Are: EVFM, BNFT, SRNE, CLRB
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has adopted a shareholder rights agreement (the "Rights Agreement"), effective March 24, 2020, under which its stockholders will receive a dividend in the form of preferred stock purchase rights (the "Rights"). The record date for the dividend has been fixed as April 8, 2020.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that the location of its annual general meeting scheduled for May 12, 2020 at 8:00 am PDT has been moved to the 6th floor boardroom at 12400 High Bluff Dr., San Diego, CA 92130.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it will participate in the upcoming 2020 RBC Capital Markets Global Healthcare Conference.
(Bloomberg) -- A new birth control gel is the first non-hormonal contraceptive to win FDA approval in decades, bringing another option to the $5.4 billion market.The gel, marketed as Phexxi by Evofem Biosciences Inc., works by making pH levels in the vagina inhospitable to sperm when applied up to an hour before sex.The approval marks a rare new option in the contraceptive market, which has been dominated by pills for the past 60 years. The last wholly new type of birth control without hormones was the female condom, approved in 1993.“This is for women who aren’t using hormonal contraceptive, who want to prevent against pregnancy and won’t use an IUD (intrauterine device),” Evofem Chief Executive Officer Saundra Pelletier said by telephone. “Our product is the only contraceptive product with no hormones, with no systemic side effects, and that women use only when they need it.”Shares of Evofem reversed an initial drop to rise 2.5% at 1:07 p.m. in New York after the thinly traded biopharmaceutical company won its first regulatory approval. The stock has fallen about 20% this year.Oppenheimer analyst Leland Gershell, who recommends investors buy shares, forecast annual sales in the U.S. could reach $440 million by 2024. The company is still working on the exact pricing, which is expected to be in-line with branded birth control pills. However, it anticipates health insurance companies will pay between $250 and $275 per pack of 12 prefilled applicators.Rather than “replace or compete with the pill” out of the gate, Pelletier said the company is looking to first target the 17 million U.S. women who identify “as beyond hormone,” meaning they either don’t want to use or can’t use a hormonal contraceptive.Currently approved hormonal products can trigger side effects like pain, nausea, headaches, bleeding, mood changes and weight gain. Traditional birth control pills can also cause blood clots and increase the risk of heart problems like a stroke or heart attack.In Phexxi trials, more than 10% of women experienced vaginal burning and itching, which was the most common side effect of the gel. However, Evofem said the events decreased with each consecutive cycle.While similar, at first glance, to over-the-counter spermicides -- which work by blocking the entrance to the cervix and slowing sperm -- the gel differs in that it uses vaginal pH levels to create an acidic environment to prevent fertilization.In a late-stage clinical study of about 1,400 women, Evofem said the gel prevented pregnancy 93.3% of the time when it was used correctly and 86% of the time overall. That compares to an effective rate for spermicides at 82% when used correctly and 72% overall, according to Planned Parenthood. The group recommends the use of spermicide in addition to another methods like condoms.Evofem is planning to start a pivotal study of the gel for the potential prevention of chlamydia and gonorrhea in women later this year, which could also boost its appeal to users and investors. It expects to start the study later this year after a mid-stage trial met its primary and secondary targets in December.The gel is expected to be available in September with a “staged launch” focused on areas where businesses shut from the coronavirus are reopening more rapidly. The company says it will also look to buck the trend of uninspiring launches for women’s health products, taking advantage of social media promotions and online influencers. The company is planning for a “very big” social push ahead of Valentine’s Day and will then expand into other media avenues, Pelletier said.(Updates share movement in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Q4 2019 Evofem Biosciences Inc Earnings Call
Image source: The Motley Fool. Evofem Biosciences, Inc. (NASDAQ: EVFM)Q1 2020 Earnings CallMay 6, 2020, 11:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by and welcome to the Evofem Biosciences Q1 2020 Financial Results Call.
Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that on April 9, 2020, the Compensation Committee of the Company's Board of Directors approved the grant to 20 new employees of (i) non-qualified stock option awards to purchase an aggregate of 357,000 shares of common stock, and (ii) 20,000 restricted shares of common stock awards in aggregate.
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM) to be made on May 21, 2020 (the "distribution date"). Based on the shares of PDL common stock outstanding as of the close of business on May 15, 2020 (the "record date"), PDL stockholders of record as of the record date will be entitled to receive 0.11591985 shares of Evofem common stock for each share of PDL common stock held as of the close of business on the record date.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present an overview of the Company and business updates at the upcoming Solebury Trout Virtual Investor Conference.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it will host a webcast and conference call to discuss the Company's financial results for the first quarter ended March 31, 2020, and provide a general business overview, on Wednesday, May 6, 2020 at 11:00 a.m. ET (8:00 a.m. PT).
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM), which represented approximately 26.7% of the outstanding shares of Evofem common stock as of the close of business on May 15, 2020 (the "record date").
Shares of the small-cap biotech Evofem Biosciences (NASDAQ: EVFM) rose by as much as 42.5% in pre-market trading Tuesday morning. The company's stock is taking flight in response to the Food and Drug Administration's (FDA) approval for the non-hormonal contraceptive vaginal gel Phexxi last Friday. This FDA approval marks the first time the agency has given the green light to a hormone-free contraceptive for women in almost 30 years.
Please note that a slide presentation to accompany management's prepared remarks is available on the Investor Relations section of the PDL website at pdl.com. Joining me today from PDL are Dominique Monnet, President and CEO; and Ed Imbrogno, Vice President and Chief Financial Officer. Please turn to Slide 2, and let me remind you that during this call, management will be making forward-looking statements regarding the Company's financial performance and other matters and actual results may differ materially from those expressed in or implied by the forward-looking statements.